Other than PD-1 and CTLA-4, indoleamine 2,3-dioxygenase-1 (IDO-1) as well as T cell immunoglobulin and mucin domain 3 (TIM-3) have recently come to the forefront in glioma immunotherapy. This evidence concerns the gene PDCD1 and central nervous system cancer.